The return of the Mashelkar report on pharma patenting in India

In a post titled The "Mashelkar Committee Report" on Pharma Patenting Resurfaces! , Spicy IP discusses how the Indian government "finalized" the Mashelkar report.
The punchline:

In short, the Committee notes, and rightly so, that any attempt to exclude an entire class of inventions i.e. incremental pharmaceutical inventions would violate the mandate under Article 27 of TRIPS to grant patents to all inventions in all fields of technology.

Readers of IPBiz may recall that there was a pretextual charge of plagiarism associated with this matter, and Spicy IP goes into that.

See also

http://ipbiz.blogspot.com/2007/07/more-mashelkar.html

http://ipbiz.blogspot.com/2008/02/on-punishing-plagiarizers-and.html